Overview

Keytruda is the brand name for pembrolizumab, a humanized monoclonal antibody developed as an immuno-oncology medicine by Merck & Co. Rather than directly attacking tumor cells in the manner of traditional cytotoxic chemotherapy, pembrolizumab acts on an immune-regulatory pathway. It binds to the programmed cell death protein 1, or PD-1, receptor on immune cells and blocks interaction with its ligands PD-L1 and PD-L2. In suitable patients, this can restore or strengthen T-cell activity against malignant cells. Treatment selection may depend on tumor type, disease stage, biomarker results such as PD-L1 expression, microsatellite instability or mismatch-repair status, and the applicable regulatory label. The scientific work that ultimately led to Keytruda began at Organon in the Netherlands in the early 2000s. After Merck acquired Schering-Plough in 2009, the program became part of Merck’s pipeline. Merck accelerated clinical development and pursued a regulatory strategy centered on immunotherapy’s potential across multiple tumor types. In 2014, the U.S. Food and Drug Administration granted an initial approval for advanced melanoma, making pembrolizumab one of the early commercial examples of PD-1 checkpoint blockade. Subsequent approvals expanded the medicine into additional melanoma settings and a wide range of solid tumors, including non-small-cell lung cancer, head and neck cancer, urothelial cancer, renal cell carcinoma, cervical cancer, gastric and esophageal cancers, and certain biomarker-defined cancers. Some indications are monotherapy uses, while others combine Keytruda with chemotherapy, radiotherapy, targeted medicines or other immunotherapies. Keytruda’s clinical and commercial importance has been driven by the breadth of its development program. Merck tested the drug in different lines of therapy, disease stages and biomarker-defined populations, including studies that established a role in first-line treatment for selected patients with advanced non-small-cell lung cancer. The brand’s growth also reflects a strategic shift in oncology marketing. Merck initially concentrated heavily on professional and medical-journal communication, but later introduced direct-to-consumer advertising that used patient narratives, biomarker education and explanations of treatment decisions. The “It’s Tru” campaign featured real patients, and later executions included an oncologist speaking about treatment alongside a patient. More recent “Known For” and “Keytruda Moment” materials frame people through their relationships, activities and aspirations while presenting the medicine as one option within physician-directed cancer care. Keytruda is administered by intravenous infusion in its conventional formulation. Merck has also pursued formulation and delivery innovations, including Keytruda QLEX, a combination of pembrolizumab and berahyaluronidase alfa-pmph intended to support subcutaneous administration where approved. Because checkpoint inhibition activates immune responses, the product carries important risks of immune-mediated adverse reactions affecting organs such as the lungs, colon, liver, kidneys, endocrine glands, skin and nervous system. Prescribing information, indication-specific evidence and local regulatory requirements therefore govern its use. The brand is a central asset in Merck’s oncology portfolio and has faced intense competition from other checkpoint inhibitors, particularly Bristol Myers Squibb’s Opdivo. Its future is also shaped by patent and exclusivity considerations, pricing and access debates, regulatory review, and Merck’s effort to develop or acquire successor oncology products and combination therapies. Keytruda remains an active global pharmaceutical brand, but its exact approved uses, formulation availability and reimbursement conditions differ by jurisdiction.

History

Keytruda’s origins lie in an antibody research program begun at Organon in the Netherlands in 2003. Scientists including Andrea van Elsas, Hans van Eenennaam and John Dulos worked on using antibody technology to influence immune regulation. The program focused on PD-1, an immune checkpoint that can be exploited by tumors to suppress T-cell activity. The resulting molecule was later known as pembrolizumab. Merck obtained the program through its 2009 acquisition of Schering-Plough, which had inherited Organon’s relevant assets. The company made pembrolizumab a priority in oncology and organized a rapid clinical and regulatory development strategy. Early trials in advanced melanoma produced responses in patients whose disease had progressed after other treatments. In September 2014, the FDA authorized Keytruda for advanced melanoma under an accelerated pathway. This approval placed Merck among the first pharmaceutical companies to commercialize a PD-1 inhibitor and gave the company a foundation for a much larger oncology franchise. Merck subsequently tested Keytruda across tumor types, stages of disease and lines of therapy. The development program explored both biomarker-selected and broader patient populations. In lung cancer, studies examined PD-L1 expression and helped establish Keytruda’s role in selected first-line and later-line non-small-cell lung cancer settings. Other programs supported approvals or label expansions in head and neck cancer, urothelial carcinoma, renal cell carcinoma, classical Hodgkin lymphoma, melanoma, cervical cancer, endometrial cancer, gastric and gastroesophageal cancers, esophageal cancer, triple-negative breast cancer and several tissue-agnostic biomarker-defined indications. The exact label has changed over time and varies between jurisdictions. A major strategic feature of Keytruda’s history has been combination development. Merck evaluated the drug with chemotherapy and with other anticancer agents, seeking to improve outcomes in diseases where immune activation alone was insufficient. The product’s clinical role consequently expanded from a treatment for a relatively narrow group of advanced melanoma patients to a platform-like medicine used in numerous oncology treatment pathways. Its success also made checkpoint inhibition a central competitive field, with Bristol Myers Squibb’s Opdivo, Roche’s Tecentriq and other immunotherapies competing for indications, prescribers and payer access. Marketing evolved alongside the clinical expansion. Merck initially relied more heavily on professional communications and medical-journal advertising than on mass-market television. From 2017, the company increased direct-to-consumer activity in lung cancer, including the “It’s Tru” campaign. The campaign used patient stories and discussed the relevance of PD-L1 testing. A later advertisement featured a real patient, while 2019 executions added practicing oncologist Goetz Kloecker to the format. Subsequent creative work, including “Keytruda Moment” and “Known For,” used broader multi-indication and human-interest narratives. These campaigns were part of a wider effort to explain immunotherapy to patients and caregivers while remaining subject to prescription-drug risk disclosures. Merck has continued to extend the brand through additional indications, combinations and delivery technologies. Keytruda QLEX combines pembrolizumab with berahyaluronidase alfa-pmph and represents an effort to provide a subcutaneous option where regulators authorize it. The formulation is linked to Merck’s broader strategy of protecting the franchise through innovation and lifecycle management. The brand’s later history has also been defined by commercial concentration and future exclusivity pressure. Keytruda became Merck’s leading product and a major driver of the company’s oncology business. Analysts and industry observers have focused on the expected loss of important patent protection later in the decade, prompting Merck to pursue new oncology assets, combinations and acquisitions that could offset the eventual decline. These corporate strategies concern the parent company rather than a change in Keytruda’s identity: Keytruda remains an active pembrolizumab brand with a broad global regulatory and clinical footprint.

2019
Real oncologist appears in “It’s Tru” advertisements
[4]Merck adds real doctor to Keytruda patient advertisementsfiercepharma.com
Merck adds oncologist Goetz Kloecker to patient-oriented Keytruda television spots.
2017
First major television advertising push
[7]First major television advertising pushfiercepharma.com
Merck begins national television advertising focused on Keytruda’s first-line NSCLC positioning and biomarker testing.
2014
Initial U.S. approval for advanced melanoma
[1]KEYTRUDA and KEYTRUDA QLEX official websitekeytruda.com
The FDA authorizes Keytruda for advanced melanoma, establishing its commercial presence in immuno-oncology.
2009
Merck gains the program through Schering-Plough acquisition
[6]The history behind Merck’s cancer immunotherapyforbes.com
Merck’s acquisition of Schering-Plough brings the developing pembrolizumab program into Merck’s pipeline.
2003
Research program begins at Organon
[5]Dutch scientists associated with Keytruda’s originslabiotech.eu
Dutch scientists at Organon begin work on the antibody program that would ultimately produce pembrolizumab.

Products and positioning

A broad-spectrum, physician-directed immuno-oncology brand positioned around PD-1 checkpoint inhibition, biomarker-informed treatment and use across multiple cancer types.

Prescription oncology immunotherapy · 2014
Keytruda
The primary pembrolizumab product, a PD-1-blocking monoclonal antibody administered by intravenous infusion. Its approved uses cover multiple cancers and biomarker-defined settings, with monotherapy and combination regimens depending on the label and jurisdiction. Immune-mediated adverse reactions are a defining safety consideration.
Subcutaneous oncology formulation
Keytruda QLEX
A formulation combining pembrolizumab with berahyaluronidase alfa-pmph. It is intended to enable subcutaneous delivery where approved, representing a lifecycle and administration innovation for the Keytruda franchise.

Marketing campaigns

2023Known For
United States
Television executions portrayed people through personal qualities, family roles, interests and aspirations while presenting Keytruda in a cancer-treatment context.
Outcome. The campaign continued Merck’s human-interest approach to prescription oncology advertising.
Source
2021The Keytruda Moment
United States
A multi-indication direct-to-consumer platform connected the moment of diagnosis with the possibility of Keytruda across numerous advanced cancers rather than focusing on one disease alone.
Outcome. The work broadened the brand’s consumer messaging across its expanding oncology indications.
Source
2019It’s Tru: real doctor and patient
United States
Two spots featured practicing oncologist Goetz Kloecker, including an advertisement in which he appeared with patient Katy. The creative emphasized physician-patient discussion and Kloecker’s clinical perspective.
Outcome. Merck said consumer feedback supported adding a real oncologist to the campaign format.
Source
2017It’s Tru
United States
Merck’s patient-centered campaign used television and digital storytelling to describe living with advanced cancer and the role of Keytruda. One later execution featured a real patient whose treatment history was connected to a PD-L1-selected NSCLC clinical program.
Outcome. The campaign expanded Keytruda’s direct-to-consumer presence and became a recognized example of real-patient pharmaceutical advertising.
Source

Brand decisions

2017
Shift toward national direct-to-consumer television advertisingStrategy
Background
Merck had initially emphasized professional and journal advertising, while rival Opdivo had already established a visible television presence.
Action taken
Merck launched national Keytruda television advertising centered first on lung cancer and patient stories.
Aftermath
Keytruda became part of a highly visible advertising contest in immuno-oncology, particularly against Opdivo.
- Bristol Myers Squibb — Bristol Myers Squibb continued promoting Opdivo through its own national advertising and competed directly for attention in immuno-oncology.
Source
Lifecycle development through an alternate delivery formulationStrategy
Background
Merck has sought to extend the Keytruda franchise through formulation and administration improvements as well as new indications.
Action taken
The company developed Keytruda QLEX, combining pembrolizumab with berahyaluronidase alfa-pmph for subcutaneous delivery where authorized.
Aftermath
The formulation’s availability and clinical use depend on regulatory approval in each market.
Source

Recent events

2021
Merck promotes multi-indication messaging through “Keytruda Moment”[8]The Keytruda Momentpharmavoice.com
Campaign
The campaign broadened consumer communication beyond a single cancer type and presented Keytruda in the context of many advanced-cancer indications.
2019
Keytruda campaign adds an oncologist and patient[4]Merck adds real doctor to Keytruda patient advertisementsfiercepharma.com
Campaign
Two advertisements featured oncologist Goetz Kloecker, including one spot with his patient, as Merck continued its real-person approach to consumer communication.
2017
Keytruda enters first-line non-small-cell lung cancer advertising competition[2]Merck unveils new Keytruda direct-to-consumer advertisementbiopharmadive.com
Campaign · Product launch
Merck began national television advertising after securing a first-line NSCLC indication, emphasizing biomarker testing and contrasting the product’s position with Opdivo.
2017
Merck features a real patient in the “It’s Tru” campaign[3]Merck adds real patient to “TRU” Keytruda television advertisementfiercepharma.com
Campaign
A national advertisement followed a patient with advanced NSCLC and connected her story to clinical evidence involving PD-L1-selected patients.
2014
FDA grants Keytruda an initial approval for advanced melanoma[1]KEYTRUDA and KEYTRUDA QLEX official websitekeytruda.com
Product launch · Regulation
The first U.S. approval established pembrolizumab as an early commercial PD-1 checkpoint inhibitor and launched the Keytruda brand in oncology.

Related entries

Merck KGaA